Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 16
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
ADMA Biologics Inc
ADMA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$10.68
-0.05
-0.47%
Dern. MÀJ: Oct 16, 4:00 PM
$10.78
0.05
0.47%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
PRO
Pourquoi cela bouge-t-il ?:
ADMA Biologics shares are trading higher after the company announced the pu...
ADMA Biologics Financials
ADMA Biologics (ADMA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est
ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.
Benzinga Newsdesk
PRO
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of $0.14 per share from
Benzinga Newsdesk
PRO
ADMA Biologics Withdraws Long-Term Guidance To Reflect Evolving U.S. Plasma Products And IG Market Competitive Dynamics
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
ADMA Biologics Sees FY2026 Sales $530.000M-$560.000M vs $632.367M Est
ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $530.000 million-$560.000 million vs $632.367 million analyst estimate.
Benzinga Newsdesk
PRO
ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.20 by 15 percent. This is a 21.43 percent increase over earnings of $0.14 per share from the
Benzinga Newsdesk
